依达拉奉联合灯盏花素注射液对腔隙性脑梗死患者认知功能的影响

Effect of Edaravone Combined with Erigeron Breviscapus(Vant)-Mazz Injection on the Cognitive Function of the Patients with Lacunar Infarction

目的:探讨依达拉奉联合灯盏花素注射液对腔隙性脑梗死患者认知功能的影响。方法:将2011年1月—2012年4月收治的76例腔隙性脑梗死患者按数字表法随机分成治疗组(n=39)和对照组(n=37)。治疗组在常规治疗基础上联合应用依达拉奉和灯盏花素注射液,将注射用灯盏花素20 mg和依达拉奉30 mg分别加入0.9%氯化钠注射液250 mL中静脉滴注;对照组则在常规治疗基础上仅用灯盏花素注射液,将注射用灯盏花素20 mg加入0.9%氯化钠注射液250 mL中静脉滴注。治疗前及治疗14 d后采用美国国立卫生院卒中量表(the National Institutes of Health Stroke Scale,NIHSS)、简易精神状态检查(mini-mental state examination,MMSE)量表及Barthel指数(Barthel index,BI)评分量表对认知功能进行评估。结果:治疗组治疗14 d后有效率为92.3%(36/39),高于对照组的70.3%(26/37),差异有统计学意义(P<0.05)。治疗14 d后治疗组NIHSS为(26.80±3.67)分,高于对照组的(19.30±4.10)分,差异有统计学意义(P<0.05);治疗组与对照组的MMSE分别为(24.16±4.21)分、(19.18±4.83)分,差异有统计学意义(P<0.05);治疗组与对照组的BI分别为64.68±17.43、35.36±11.69,差异有统计学意义(P<0.05)。结论:依达拉奉联合灯盏花素注射液可有效改善腔隙性脑梗死患者的认知功能。

Objective：To investigate the effect of edaravone combined with Erigeron breviscapus（Vant）-Mazz injection on the cognitive function of the patients with lacunar infaretion. Methods： A total of 76 patients with laeunar infarction from Jan 2011 to Apr 2（112 were randomly divided into edaravone group（n = 39） and control group（n = 37） according to random number table. Patients in edaravone group were treated with edaravone at a dose of 20 mg combined with Erigeron breviscapus（Vant）-Mazz iniection at a dose of 30 mg （added into 250 mL 0.9% sodium chloride solution respectively）. Patients in control group（n= 37） were treated with Erigeron breviscapus（Vant） Mazz injetion at a dose of 30 mg （added into 250 ml. 0.9% sodium chloride solu tion）. Before treatment and after 14 d treatment, scores of the National Institutes of Health Stroke Scale（NIHSS）, mini mental state examination（MMSE） and Barthel index（BI）were used to evaluate the cognitive function. Results; After 14 d treatment, the effective rate of control group was 92.3 % （36/39）, while the effective rate of control group was 70.3 % （26/37）,and the difference was significant（P〈0.05）. The score of NIHSS in edaravone group（26.80 ± 3.67）was significantly higher than that in control group（ 19.30 ± 4.10）, and the difference was significant（P〈0.05 ）. The score of MMSE in edaravone group（24.16 ± 4.21 ）was significantly higher than that in control group （19. 18 ± 4. 83）, and the difference was significant （P 〈 0. 05 ）. The score of BI in edaravone group（64.68 ± 17.43）was significantly higher than that in control group（35. 36 ± 11. 69）, and the difference was significant（P〈%0.05）. Conclusions.. Edaravone combined with Erigeron breviscapus （ Vant）-Mazz injection can improve the cognitive functions of the patients with lacunar infarction.